home / open_comments

documents

Federal regulatory documents currently open for public comment. ⚠ Derive comment deadlines from comment_end_datetime converted to America/New_York, never from comment_end_date, which is mid-correction and may be one day late (DataDawn queue #498).

Data license: Public Domain (U.S. Government data) · Data source: Regulations.gov API (General Services Administration)

perpetual_docket
1 = a standing/perpetual docket carrying a sentinel comment-end date (2050 or later; in practice 2099/2100 — agency guidance and exemption dockets that never close). 0 = an ordinary docket with a real deadline. NULL = no end date reported. The site's Open-for-Comment surface EXCLUDES perpetual_docket = 1 by default, so the site count and the bulk dump answer the same question differently: the dump is complete and includes them.
comment_end_date
The comment deadline as an Eastern (America/New_York) calendar date — CORRECTED in the 2026-09-06 daily snapshot (DataDawn queue #498): a snapshot whose _metadata row comment_end_date_grain reads 'eastern' carries the Eastern date; the pre-correction snapshots (through 2026-09-05) held the UTC-rolled day, one day LATE on every end-of-day close. Federal comment periods close at 11:59:59 PM Eastern and the source publishes that instant in UTC ('2026-08-26T03:59:59Z' = the 2026-08-25 deadline). Prefer comment_end_datetime for any arithmetic and convert it to America/New_York yourself; never 'subtract a day' from this column.
comment_end_datetime
AUTHORITATIVE. The full UTC instant of the comment deadline ('2026-08-26 03:59:59' == 11:59:59 PM Eastern on 2026-08-25). Convert to America/New_York for the official date; prefer this column over comment_end_date for anything computed.

93 rows where agency_id = "FDA" sorted by comment_end_datetime descending

✎ View and edit SQL

This data as json, CSV (advanced)

document_type 4

  • Other 47
  • Notice 35
  • Proposed Rule 8
  • Rule 3

agency_id 1

  • FDA · 93 ✖
id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date comment_end_datetime ▲ perpetual_docket last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2015-N-3469-0001 FDA FDA-2015-N-3469 Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket Notice Notice of Availability 2015-10-27 2015 10 2015-10-27 2050-02-21 2050-02-22 04:59:59 1 2026-08-11 09:00:50 2015-27270 1 0 0900006481cf17b1
FDA-2015-N-3534-0001 FDA FDA-2015-N-3534 Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket Notice Notice of Availability 2015-10-27 2015 10 2015-10-27 2050-02-21 2050-02-22 04:59:59 1 2026-09-20 09:00:16 2015-27271 1 0 0900006481cf1710
FDA-2011-N-0656-1315 FDA FDA-2011-N-0656 Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate Notice General Notice 2026-05-11 2026 5 2026-05-11 2027-12-01 2027-12-02 04:59:59 0 2026-08-13 14:40:33 2026-09283 1 0 09000064b92cacd0
FDA-2011-N-0655-0042 FDA FDA-2011-N-0655 Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Generic Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate Notice Notice of Intent 2026-05-11 2026 5 2026-05-11 2027-12-01 2027-12-02 04:59:59 0 2026-08-13 14:41:39 2026-09284 1 0 09000064b92cf91b
FDA-2011-N-0656-1314 FDA FDA-2011-N-0656 Animal Drug User Fee Act; Public Meeting; Request for Comments Notice Request for Comments 2026-04-17 2026 4 2026-04-17 2027-12-01 2027-12-02 04:59:59 0 2026-08-20 09:01:12 2026-07498 1 0 09000064b928948d
FDA-2011-N-0655-0041 FDA FDA-2011-N-0655 Animal Generic Drug User Fee Act; Public Meeting; Request for Comments Notice Request for Comments 2026-04-17 2026 4 2026-04-17 2027-12-01 2027-12-02 04:59:59 0 2026-10-29 09:00:22 2026-07497 1 0 09000064b928930a
FDA-2026-N-10832-0001 FDA FDA-2026-N-10832 Infant Formula Nutrient Requirements Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-11-02 2026 11 2026-11-02 2027-03-02 2027-03-03 04:59:59 0 2026-11-22 10:00:39 2026-22273 1 0 09000064b96c7f91
FDA-2024-D-2560-0035 FDA FDA-2024-D-2560 Essential Drug Delivery Performance Characteristics for Devices Intended To Deliver Drugs and Biological Products; Revised Draft Guidance for Industry; Availability Notice Notice of Availability 2026-10-30 2026 10 2026-10-30 2027-01-28 2027-01-29 04:59:59 0 2026-10-30 18:34:42 2026-22203 1 0 09000064b96bf3a4
FDA-2024-D-2560-0036 FDA FDA-2024-D-2560 Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products; Guidance for Industry - Draft Guidance Other Guidance 2026-10-30 2026 10 2026-10-30 2027-01-28 2027-01-29 04:59:59 0 2026-11-03 10:00:32   1 0 09000064b96bf48f
FDA-2026-N-7864-0001 FDA FDA-2026-N-7864 Data Request (DR001): Use of the pH Cycling Test Model as a Testing Procedure for Fluoride Dentifrice Drug Products in Over-the-Counter (OTC) Monograph M021: Anticaries Drug Products for Over-the-Counter Human Use Other Request 2026-07-28 2026 7 2026-07-28 2027-01-25 2027-01-26 04:59:59 0 2026-07-28 16:50:16   1 0 09000064b93c7444
FDA-2016-D-2343-3655 FDA FDA-2016-D-2343 Hazard Analysis and Risk-Based Preventive Controls for Human Food; Draft Guidance for Industry; Availability Proposed Rule GDL Guidance 2026-10-23 2026 10 2026-10-23 2027-01-21 2027-01-22 04:59:59 0 2026-10-24 09:01:08 2026-21669 1 0 09000064b969a7c0
FDA-2016-D-2343-3656 FDA FDA-2016-D-2343 Hazard Analysis and Risk-Based Preventive Controls for Human Food: Draft Guidance for Industry - Chapter 12: Control of Chemical Hazards Other Guidance 2026-10-23 2026 10 2026-10-23 2027-01-21 2027-01-22 04:59:59 0 2026-11-18 10:01:00   1 0 09000064b969688b
FDA-2025-N-2699-0001 FDA FDA-2025-N-2699 Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-11-17 2026 11 2026-11-17 2027-01-19 2027-01-20 04:59:59 0 2026-11-18 10:01:08 2026-23351 1 0 09000064b972320a
FDA-2026-N-9703-0001 FDA FDA-2026-N-9703 Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing Notice Notice of Opportunity of Hearing 2026-11-18 2026 11 2026-11-18 2027-01-19 2027-01-20 04:59:59 0 2026-11-18 19:49:27 2026-23413 1 0 09000064b97280d0
FDA-2007-D-0369-2751 FDA FDA-2007-D-0369 Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability Notice Notice of Availability 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 20:25:56 2026-23692 1 0 09000064b97314c7
FDA-2007-D-0369-2752 FDA FDA-2007-D-0369 PSG_219083 - Draft Guidance on Aficamten Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:37:55   1 0 09000064b972e48c
FDA-2007-D-0369-2753 FDA FDA-2007-D-0369 PSG_205636 - Draft Guidance on Albuterol Sulfate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:38:07   1 0 09000064b972e497
FDA-2007-D-0369-2754 FDA FDA-2007-D-0369 PSG_016324 - Draft Guidance on Azathioprine Other Background Material 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:38:32   1 0 09000064b972e49d
FDA-2007-D-0369-2755 FDA FDA-2007-D-0369 PSG_219840 - Draft Guidance on Barium Sulfate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:38:48   1 0 09000064b972eea0
FDA-2007-D-0369-2756 FDA FDA-2007-D-0369 PSG_219776 - Draft Guidance on Berotralstat Dihydrochloride Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:39:10   1 0 09000064b972eea2
FDA-2007-D-0369-2757 FDA FDA-2007-D-0369 PSG_019845 - Draft Guidance on Betaxolol Hydrochloride Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:39:39   1 0 09000064b972f04c
FDA-2007-D-0369-2758 FDA FDA-2007-D-0369 PSG_219500 - Draft Guidance on Bumetanide Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:39:55   1 0 09000064b972f063
FDA-2007-D-0369-2759 FDA FDA-2007-D-0369 PSG_215430 - Draft Guidance on Bupropion Hydrochloride; Dextromethorphan Hydrobromide Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:40:14   1 0 09000064b972f069
FDA-2007-D-0369-2760 FDA FDA-2007-D-0369 PSG_008915 - Draft Guidance on Carbinoxamine Maleate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:40:30   1 0 09000064b972f09e
FDA-2007-D-0369-2761 FDA FDA-2007-D-0369 PSG_219155 - Draft Guidance on Delgocitinib Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:40:51   1 0 09000064b972f0a0
FDA-2007-D-0369-2762 FDA FDA-2007-D-0369 PSG_215400 - Draft Guidance on Dihydroergotamine mesylate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:41:04   1 0 09000064b972f0a2
FDA-2007-D-0369-2763 FDA FDA-2007-D-0369 PSG_020216 - Draft Guidance on Conjugated Estrogens Other Background Material 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:41:26   1 0 09000064b972f0a4
FDA-2007-D-0369-2764 FDA FDA-2007-D-0369 PSG_218718 - Draft Guidance on Ethinyl Estradiol; Norethindrone Acetate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:41:40   1 0 09000064b972f0ab
FDA-2007-D-0369-2765 FDA FDA-2007-D-0369 PSG_022399 - Draft Guidance on Gabapentin Enacarbil Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:41:52   1 0 09000064b972f0ae
FDA-2007-D-0369-2766 FDA FDA-2007-D-0369 PSG_218881 - Draft Guidance on Imlunestrant Tosylate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:42:12   1 0 09000064b972f0b4
FDA-2007-D-0369-2767 FDA FDA-2007-D-0369 PSG_208462 - Draft Guidance on Ixazomib Citrate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:42:24   1 0 09000064b972f0b7
FDA-2007-D-0369-2768 FDA FDA-2007-D-0369 PSG_218879 - Draft Guidance on Lamotrigine Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:42:48   1 0 09000064b972f0bc
FDA-2007-D-0369-2769 FDA FDA-2007-D-0369 PSG_022074 - Draft Guidance on Lanreotide Acetate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:43:01   1 0 09000064b972f0c0
FDA-2007-D-0369-2770 FDA FDA-2007-D-0369 PSG_206947 - Draft Guidance on Lenvatinib Mesylate Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:43:16   1 0 09000064b972f0c3
FDA-2007-D-0369-2771 FDA FDA-2007-D-0369 PSG_021897 - Draft Guidance on Naltrexone Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:43:31   1 0 09000064b972f0c6
FDA-2007-D-0369-2772 FDA FDA-2007-D-0369 PSG_218764 - Draft Guidance on Nerandomilast Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:43:45   1 0 09000064b972f0cb
FDA-2007-D-0369-2773 FDA FDA-2007-D-0369 PSG_018705 - Draft Guidance on Nitroglycerin Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:43:56   1 0 09000064b972f0cf
FDA-2007-D-0369-2774 FDA FDA-2007-D-0369 PSG_220934 - Draft Guidance on Orforglipron Calcium Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:44:13   1 0 09000064b972f0d4
FDA-2007-D-0369-2775 FDA FDA-2007-D-0369 PSG_219070 - Draft Guidance on Paltusotine Hydrochloride Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:44:28   1 0 09000064b972f0d7
FDA-2007-D-0369-2776 FDA FDA-2007-D-0369 PSG_009829 - Draft Guidance on Pyridostigmine Bromide Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:44:40   1 0 09000064b972f0dc
FDA-2007-D-0369-2777 FDA FDA-2007-D-0369 PSG_218436 - Draft Guidance on Remibrutinib Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:44:51   1 0 09000064b972f0e2
FDA-2007-D-0369-2778 FDA FDA-2007-D-0369 PSG_219666 - Draft Guidance on Sepiapterin Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:45:24   1 0 09000064b972f0e7
FDA-2007-D-0369-2779 FDA FDA-2007-D-0369 PSG_211527 - Draft Guidance on Trifarotene Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:45:35   1 0 09000064b972f0ef
FDA-2007-D-0369-2780 FDA FDA-2007-D-0369 PSG_219042 - Draft Guidance on Zongertinib Other Guidance 2026-11-20 2026 11 2026-11-20 2027-01-19 2027-01-20 04:59:59 0 2026-11-20 21:46:14   1 0 09000064b972f0f6
FDA-2026-D-13432-0001 FDA FDA-2026-D-13432 Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; Availability Notice Notice of Availability 2026-11-12 2026 11 2026-11-12 2027-01-11 2027-01-12 04:59:59 0 2026-11-12 20:07:17 2026-22970 1 0 09000064b970f43a
FDA-2026-N-12575-0001 FDA FDA-2026-N-12575 Agency Information Collection Activities; Proposed Collection; Comment Request; Voluntary Qualified Importer Program Notice 60 Day Proposed Information Collection 2026-11-12 2026 11 2026-11-12 2027-01-11 2027-01-12 04:59:59 0 2026-11-12 21:13:03 2026-22965 1 0 09000064b970f2e0
FDA-2026-N-12508-0001 FDA FDA-2026-N-12508 Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product Proposed Rule Request for Comment 2026-11-12 2026 11 2026-11-12 2027-01-11 2027-01-12 04:59:59 0 2026-11-14 10:00:56 2026-23005 1 0 09000064b970f439
FDA-2026-N-12280-0001 FDA FDA-2026-N-12280 Agency Information Collection Activities; Proposed Collection; Comment Request; Veterinary Feed Directive Notice 60 Day Proposed Information Collection 2026-11-12 2026 11 2026-11-12 2027-01-11 2027-01-12 04:59:59 0 2026-11-17 10:00:46 2026-22964 1 0 09000064b970f432
FDA-2026-D-13432-0002 FDA FDA-2026-D-13432 Early-Phase IND Protocol Recommendations for Solid Tumors; Guidance for Industry - Draft Guidance Other Guidance 2026-11-12 2026 11 2026-11-12 2027-01-11 2027-01-12 04:59:59 0 2026-11-22 00:27:28   1 0 09000064b970fd58
FDA-2026-N-10742-0001 FDA FDA-2026-N-10742 Patient-Level Data for Drugs and Biological Products Submissions Containing Real-World Data and Real-World Evidence; Request for Information Notice Requests for Information (RFI) 2026-11-12 2026 11 2026-11-12 2027-01-11 2027-01-12 04:59:59 0 2026-11-22 10:00:42 2026-22996 1 0 09000064b970f47e
FDA-2026-N-13135-0002 FDA FDA-2026-N-13135 Public Workshop: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities Other Meeting 2026-11-06 2026 11 2026-11-06 2027-01-05 2027-01-06 04:59:59 0 2026-11-06 22:14:03   1 0 09000064b96f2a4f
FDA-2026-N-13135-0001 FDA FDA-2026-N-13135 Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities: Discussion Paper and Request for Feedback Other Request 2026-11-06 2026 11 2026-11-06 2027-01-05 2027-01-06 04:59:59 0 2026-11-19 10:01:08   1 0 09000064b96f2a4d
FDA-2026-N-0131-0001 FDA FDA-2026-N-0131 FDA Rare Disease Innovation Hub Future Programming; Request for Comments Notice Request for Comments 2026-01-30 2026 1 2026-01-30 2026-12-31 2027-01-01 04:59:59 0 2026-10-27 09:00:12 2026-01903 1 0 09000064b91893ee
FDA-2026-D-6729-0001 FDA FDA-2026-D-6729 U.S.-Origin Statements on Seafood; Draft Guidance for Industry; Availability Notice Notice of Availability 2026-10-27 2026 10 2026-10-27 2026-12-28 2026-12-29 04:59:59 0 2026-10-28 09:00:50 2026-21838 1 0 09000064b96a7ffd
FDA-2023-N-3743-0004 FDA FDA-2023-N-3743 Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Records; Electronic Signatures Notice 60 Day Proposed Information Collection 2026-10-28 2026 10 2026-10-28 2026-12-28 2026-12-29 04:59:59 0 2026-10-28 18:13:57 2026-21908 1 0 09000064b96b00ae
FDA-2026-N-11301-0001 FDA FDA-2026-N-11301 Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Participation in Food and Drug Administration Fellowship and Traineeship Programs Notice 60 Day Proposed Information Collection 2026-10-28 2026 10 2026-10-28 2026-12-28 2026-12-29 04:59:59 0 2026-10-28 18:17:19 2026-21914 1 0 09000064b96b0076
FDA-2026-D-11188-0002 FDA FDA-2026-D-11188 Electronic Submission Template for Investigational Device Exemption (IDE) Applications; Draft Guidance for Sponsors and Food and Drug Administration Staff Other Guidance 2026-10-28 2026 10 2026-10-28 2026-12-28 2026-12-29 04:59:59 0 2026-10-31 09:01:08   1 0 09000064b96afd8f
FDA-2026-D-6729-0002 FDA FDA-2026-D-6729 U.S.-Origin Statements on Seafood: Guidance for Industry - Draft Guidance Other Guidance 2026-10-27 2026 10 2026-10-27 2026-12-28 2026-12-29 04:59:59 0 2026-11-10 10:01:36   1 0 09000064b96a652d
FDA-2026-N-11623-0001 FDA FDA-2026-N-11623 Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Rapid Response Surveys Notice 60 Day Proposed Information Collection 2026-10-28 2026 10 2026-10-28 2026-12-28 2026-12-29 04:59:59 0 2026-11-10 10:01:37 2026-21912 1 0 09000064b96b00b1
FDA-2026-N-11261-0001 FDA FDA-2026-N-11261 Agency Information Collection Activities; Proposed Collection; Comment Request; Product Jurisdiction and Combination Products Notice 60 Day Proposed Information Collection 2026-10-23 2026 10 2026-10-23 2026-12-22 2026-12-23 04:59:59 0 2026-10-23 18:44:26 2026-21713 1 0 09000064b969a84f
FDA-2026-N-11074-0001 FDA FDA-2026-N-11074 Agency Information Collection Activities; Proposed Collection; Comment Request; Export Certificates for FDA Regulated Products Notice 60 Day Proposed Information Collection 2026-10-23 2026 10 2026-10-23 2026-12-22 2026-12-23 04:59:59 0 2026-10-23 18:53:29 2026-21714 1 0 09000064b969a7fb
FDA-2025-D-4023-0001 FDA FDA-2025-D-4023 Action Levels for Cadmium in Processed Food Intended for Babies and Young Children; Draft Guidance for Industry; Availability Proposed Rule GDL Guidance 2026-10-23 2026 10 2026-10-23 2026-12-22 2026-12-23 04:59:59 0 2026-10-24 09:01:08 2026-21670 1 0 09000064b969a7c2
FDA-2025-D-4023-0002 FDA FDA-2025-D-4023 Action Levels for Cadmium in Processed Food Intended for Babies and Young Children: Draft Guidance for Industry; Draft Guidance Other Guidance 2026-10-23 2026 10 2026-10-23 2026-12-22 2026-12-23 04:59:59 0 2026-11-20 10:00:21   1 0 09000064b9687f85
FDA-2026-N-3532-0005 FDA FDA-2026-N-3532 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies Notice 30 Day Proposed Information Collection 2026-11-19 2026 11 2026-11-19 2026-12-21 2026-12-22 04:59:59 0 2026-11-19 19:15:11 2026-23541 1 0 09000064b972c82f
FDA-2026-N-3070-0010 FDA FDA-2026-N-3070 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Youth Tobacco Survey Notice 30 Day Proposed Information Collection 2026-11-19 2026 11 2026-11-19 2026-12-21 2026-12-22 04:59:59 0 2026-11-19 19:31:57 2026-23542 1 0 09000064b972e113
FDA-2026-N-12214-0001 FDA FDA-2026-N-12214 Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and Comments Notice Request for Comments 2026-10-16 2026 10 2026-10-16 2026-12-11 2026-12-12 04:59:59 0 2026-11-22 00:24:54 2026-21142 1 0 09000064b9676453
FDA-2023-C-5679-0039 FDA FDA-2023-C-5679 Color Additive Petition From Environmental Defense Fund et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene Rule Final Rule 2026-11-10 2026 11 2026-11-10 2026-12-10 2026-12-11 04:59:59 0 2026-11-12 10:01:38 2026-22865 1 0 09000064b9701131
FDA-2026-C-3071-0006 FDA FDA-2026-C-3071 Color Additive Petition From the International Association of Color Manufacturers; Request To Amend the Color Additive Regulations To Remove the Solvents Methylene Chloride, Trichloroethylene, and Ethylene Dichloride Rule Final Rule 2026-11-10 2026 11 2026-11-10 2026-12-10 2026-12-11 04:59:59 0 2026-11-19 10:01:08 2026-22866 1 0 09000064b9701220
FDA-2025-N-3262-0001 FDA FDA-2025-N-3262 Substances Generally Recognized as Safe Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-08-11 2026 8 2026-08-11 2026-12-09 2026-12-10 04:59:59 0 2026-11-22 10:00:29 2026-16296 1 0 09000064b942ea41
FDA-2020-E-1882-0005 FDA FDA-2020-E-1882 Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC Notice Determinations 2026-10-09 2026 10 2026-10-09 2026-12-08 2026-12-09 04:59:59 0 2026-10-09 18:22:03 2026-20766 1 0 09000064b9657798
FDA-2020-E-1892-0005 FDA FDA-2020-E-1892 Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC Notice Determinations 2026-10-09 2026 10 2026-10-09 2026-12-08 2026-12-09 04:59:59 0 2026-10-09 18:23:55 2026-20766 1 0 09000064b965705e
FDA-2026-N-10605-0001 FDA FDA-2026-N-10605 Agency Information Collection Activities; Proposed Collection; Comment Request; Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations Notice 60 Day Proposed Information Collection 2026-10-08 2026 10 2026-10-08 2026-12-07 2026-12-08 04:59:59 0 2026-10-08 17:22:43 2026-20663 1 0 09000064b9651d3d
FDA-2026-N-5347-0001 FDA FDA-2026-N-5347 Nonclinical Testing Terminology Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-09-22 2026 9 2026-09-22 2026-12-07 2026-12-08 04:59:59 0 2026-11-22 10:00:31 2026-19349 1 0 09000064b95ae769
FDA-2026-N-5347-0002 FDA FDA-2026-N-5347 Nonclinical Testing Terminology Rule Direct Final Rule 2026-09-22 2026 9 2026-09-22 2026-12-07 2026-12-08 04:59:59 0 2026-11-22 10:00:31 2026-19350 1 0 09000064b95ae59d
FDA-2014-N-0053-1398 FDA FDA-2014-N-0053 Challenges and Solutions in Lot-Level Food Traceability; Public Meeting Notice Public Meetings 2026-10-09 2026 10 2026-10-09 2026-12-06 2026-12-07 04:59:59 0 2026-11-19 10:01:04 2026-20720 1 0 09000064b9653e73
FDA-2026-D-8693-0002 FDA FDA-2026-D-8693 Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Guidance for Industry; Draft Guidance for Industry Other Guidance 2026-09-02 2026 9 2026-09-02 2026-12-01 2026-12-02 04:59:59 0 2026-09-03 00:56:30   1 0 09000064b94bc729
FDA-2026-D-8693-0001 FDA FDA-2026-D-8693 Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability Notice Notice of Availability 2026-09-02 2026 9 2026-09-02 2026-12-01 2026-12-02 04:59:59 0 2026-09-03 18:40:25 2026-17961 1 0 09000064b94bf507
FDA-2026-N-10132-0001 FDA FDA-2026-N-10132 Agency Information Collection Activities; Proposed Collection; Comment Request; Protection of Human Subjects and Institutional Review Boards Notice 60 Day Proposed Information Collection 2026-09-29 2026 9 2026-09-29 2026-11-30 2026-12-01 04:59:59 0 2026-10-23 09:00:38 2026-19849 1 0 09000064b95e7083
FDA-2012-N-1021-0107 FDA FDA-2012-N-1021 Instructions for Submitting Comments on the CDRH Fiscal Year 2027 Proposed Guidance Development Other Additional Information 2026-10-01 2026 10 2026-10-01 2026-11-30 2026-12-01 04:59:59 0 2026-11-18 10:00:50   1 0 09000064b95fb842
FDA-2018-D-4533-2363 FDA FDA-2018-D-4533 Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request Notice Notice of Availability 2026-08-28 2026 8 2026-08-28 2026-11-27 2026-11-28 04:59:59 0 2026-08-28 16:31:49 2026-17580 1 0 09000064b94a6448
FDA-2026-N-2742-0002 FDA FDA-2026-N-2742 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Color Additive Certification Notice 30 Day Proposed Information Collection 2026-10-28 2026 10 2026-10-28 2026-11-27 2026-11-28 04:59:59 0 2026-10-28 17:35:55 2026-21913 1 0 09000064b96b0189
FDA-2026-D-11783-0001 FDA FDA-2026-D-11783 Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability Notice Notice of Availability 2026-10-28 2026 10 2026-10-28 2026-11-27 2026-11-28 04:59:59 0 2026-10-28 17:49:35 2026-21954 1 0 09000064b96b00b6
FDA-2018-D-4533-2364 FDA FDA-2018-D-4533 Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities; Draft Guidance Other Guidance 2026-08-28 2026 8 2026-08-28 2026-11-27 2026-11-28 04:59:59 0 2026-11-22 10:00:30   1 0 09000064b94a6e26
FDA-2026-D-11783-0002 FDA FDA-2026-D-11783 Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry Other Guidance 2026-10-28 2026 10 2026-10-28 2026-11-27 2026-11-28 04:59:59 0 2026-11-22 10:00:37   1 0 09000064b96a45c1
FDA-2015-N-3326-0056 FDA FDA-2015-N-3326 Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments Notice Request for Comments 2026-09-25 2026 9 2026-09-25 2026-11-25 2026-11-26 04:59:59 0 2026-11-21 10:00:45 2026-19660 1 0 09000064b95c53b7
FDA-2026-P-5995-0001 FDA FDA-2026-P-5995 Suitability Petition from Hyman, Phelps, & McNamara P.C. Other Petition(s) 2026-05-28 2026 5 2026-05-28 2026-11-24 2026-11-25 04:59:59 0 2026-09-29 15:44:43   1 0 09000064b92f59e1
FDA-2026-N-8563-0001 FDA FDA-2026-N-8563 Regulatory Science Innovations Catalyzing Medical Device Development_Co-sponsored Public Meeting Other Meeting 2026-08-06 2026 8 2026-08-06 2026-11-24 2026-11-25 04:59:59 0 2026-11-06 10:00:29   1 0 09000064b940e756
FDA-2026-N-9505-0002 FDA FDA-2026-N-9505 Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance Other Guidance 2026-09-25 2026 9 2026-09-25 2026-11-24 2026-11-25 04:59:59 0 2026-11-21 10:00:46   1 0 09000064b95c6e19
FDA-2025-D-6952-0001 FDA FDA-2025-D-6952 Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants; Draft Guidance for Industry; Availability Proposed Rule Notice of Proposed Rulemaking (NPRM) 2026-10-09 2026 10 2026-10-09 2026-11-23 2026-11-24 04:59:59 0 2026-10-09 17:58:29 2026-20721 1 0 09000064b96577e1
FDA-2026-N-7130-0004 FDA FDA-2026-N-7130 Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Accreditation Scheme for Conformity Assessment Program Notice 30 Day Proposed Information Collection 2026-10-23 2026 10 2026-10-23 2026-11-23 2026-11-24 04:59:59 0 2026-11-04 10:00:37 2026-21712 1 0 09000064b969a84d
FDA-2025-D-6952-0002 FDA FDA-2025-D-6952 Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants: Guidance for Industry - Draft Guidance Other Guidance 2026-10-09 2026 10 2026-10-09 2026-11-23 2026-11-24 04:59:59 0 2026-11-15 10:00:32   1 0 09000064b96574d6
FDA-2026-N-13038-0001 FDA FDA-2026-N-13038 FDA/Office of Generic Drugs to Interested Parties; Request for Comments – Letter Other Letter(s) 2026-10-23 2026 10 2026-10-23 2026-11-23 2026-11-24 04:59:59 0 2026-11-21 10:00:55   1 0 09000064b969a8da
FDA-2026-N-10100-0001 FDA FDA-2026-N-10100 FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in Biologics Notice Meeting 2026-08-31 2026 8 2026-09-23 2026-11-22 2026-11-23 04:59:59 0 2026-11-22 00:19:58   1 0 09000064b94b538f

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
            id TEXT PRIMARY KEY,
            agency_id TEXT,
            docket_id TEXT,
            title TEXT,
            document_type TEXT,
            subtype TEXT,
            posted_date TEXT,
            posted_year INTEGER,
            posted_month INTEGER,
            comment_start_date TEXT,
            comment_end_date TEXT,      -- EASTERN calendar date of the close (queue #498 writer
                                        -- fix, 2026-09-05; was the UTC-rolled day AFTER the ET
                                        -- deadline before that). Display-grade only.
            comment_end_datetime TEXT,  -- full UTC close ("YYYY-MM-DD HH:MM:SS", queue #498):
                                        -- the API expresses the 11:59:59 PM ET deadline as a UTC
                                        -- datetime. AUTHORITATIVE: the predicate, days_left and
                                        -- any timezone-aware render derive from THIS column.
            perpetual_docket INTEGER,   -- 1 = sentinel end date (queue #464); NULL = no end date
            last_modified TEXT,
            fr_doc_num TEXT,
            open_for_comment INTEGER,
            withdrawn INTEGER,
            object_id TEXT
        );
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date);
CREATE INDEX idx_docs_withdrawn ON documents(withdrawn);
CREATE INDEX idx_docs_perpetual ON documents(perpetual_docket);
Powered by Datasette · Queries took 2.718ms · Data license: Public Domain (U.S. Government data) · Data source: Regulations.gov API (General Services Administration) · Privacy